J

Johnson & Johnson

Makes prescription drugs and medical devices

Automation Engineering Manager – Drug Product Manufacturing Lead

Full-TimeDeadline 9/30/26
No salary listed
Senior, Expert
Bachelor's
Wilson, NC, USA
In PersonFull-time on-site support is required; travel exceeding 25% is expected until the project shifts to the Wilson plant site.
Engineering ManagementEngineering Leadership

About the job

Requirements
  • A minimum Bachelor's degree in Engineering, Computer Science, Science, or a related technical discipline.
  • Minimum of 8 years of progressive industrial automation and controls engineering experience in pharmaceutical or biopharmaceutical manufacturing, including direct technical ownership for the design, implementation, commissioning, qualification, troubleshooting, and lifecycle management of automated manufacturing systems in a cGMP environment.
  • Demonstrated Drug Product automation experience supporting sterile or aseptic manufacturing operations, including formulation, aseptic filling/finish, optical or visual inspection, device assembly, packaging, robotics, or other highly automated Drug Product manufacturing processes.
  • Proven leadership experience directing automation and controls engineers, technical professionals, contractors, OEM automation teams, suppliers, and system integrators, with accountability for technical direction, resource planning, issue resolution, and delivery of automation scope.
  • Deep technical knowledge of ISA-95 Level 1 and Level 2 manufacturing automation systems, including DCS, PLC, SCADA/HMI, batch control, machine controls, servo/motion control, vision and inspection systems, robotics, industrial networks, communication protocols, OT infrastructure, and related hardware and system interfaces.
  • Experience integrating manufacturing automation with Level 3 systems such as MES, historian, recipe management, data platforms, and related business or quality systems, including interface definition, data-flow mapping, and troubleshooting across systems.
  • Working knowledge of ISA-88 and ISA-95 standards and their application within regulated manufacturing, capital project, and global supply-chain environments.
  • Strong understanding of cGMP and computerized system validation expectations, including GAMP 5, 21 CFR Part 11, EU GMP Annex 11, data integrity, and risk-based validation principles.
  • Demonstrated automation project execution experience, including controls design reviews, OEM and system integrator management, FAT/SAT, commissioning, qualification, risk management, automation change control, troubleshooting, and start-up support within a complex pharmaceutical manufacturing or capital-project environment.
  • Strong communication and stakeholder-management skills, with the ability to influence, align, and partner effectively with Automation, Manufacturing, Engineering, Quality, CSV, OT Infrastructure, Digital, project leadership, and senior management teams.
  • Ability and willingness to support project travel and on-site execution needs across design, construction, start-up, and steady-state phases, including travel to supplier, OEM, system integrator, and Johnson & Johnson affiliate sites as required.
Responsibilities
  • Lead, coach, and develop the Drug Product automation team and extended delivery organization, including automation engineers, controls engineers, system integrators, OEM automation teams, and contractors; provide resource planning, technical direction, capability development, performance alignment, and delivery accountability.
  • Define and implement the Drug Product automation strategy, technical scope, control-system architecture, standards, software and configuration practices, and lifecycle roadmap; ensure the resources, governance, and processes required for successful automation delivery are in place.
  • Provide end-to-end automation engineering leadership from concept and detailed design through controls development, FAT/SAT, construction support, commissioning, qualification, start-up, handover, troubleshooting, and steady-state lifecycle support.
  • Lead the technical design authority for Drug Product automation solutions supporting formulation, aseptic filling, optical and visual inspection, device assembly, packaging, robotics, and material handling.
  • Provide technical oversight of PLC/DCS control systems, SCADA/HMI, batch control, machine and motion control, vision/inspection systems, robotics, industrial networks, OT infrastructure, and interfaces with MES, historians, and other site systems.
  • Review and approve automation engineering work, including control strategies, functional and design specifications, control narratives, system architectures, interface definitions, software/configuration standards, FAT/SAT protocols, commissioning and qualification documentation, and automation change controls.
  • Ensure automation work and system lifecycle practices comply with global standards, cGMP requirements, GAMP 5 expectations, data integrity principles, cybersecurity controls, and applicable validation requirements.
  • Support inspections, risk assessments, investigations, deviations, corrective and preventive actions, and timely remediation activities related to Drug Product automation systems.
  • Manage project cost, quality, schedule, scope, resources, and risk; remove obstacles, maintain accurate execution plans, and raise key decisions or issues to senior business and project team members as needed.
  • Build effective partnerships with Manufacturing, Process Engineering, Quality, Computerized System Validation, OT Infrastructure, MES, BAS and Utilities, Lab Systems, Procurement, Digital, and other cross-functional partners.
  • Serve as the primary Drug Product automation point of contact for the site and ensure integrated delivery with process, equipment, digital, and manufacturing teams.
  • Define, monitor, and report meaningful metrics and key performance indicators for project delivery, system performance, compliance, reliability, and lifecycle health.
  • Lead technical selection, alignment, performance management, and delivery governance for automation suppliers, OEM controls teams, system integrators, and automation service providers.
  • Ensure supplier designs, software, and integration work align with site automation architecture, standards, cybersecurity, validation, and lifecycle requirements.
  • Develop and maintain reusable design standards, specifications, libraries, templates, and engineering practices that support consistent, maintainable, and scalable automation solutions.
  • Ensure operational readiness through effective support models, training, documentation, maintenance strategies, spare-parts planning, disaster recovery, business continuity, and system ownership arrangements.
  • Use industry experience and operational data to identify and lead continuous improvement opportunities across automation, validation, reliability, manufacturing performance, and digital enablement.
Desired Qualifications
  • Experience with aseptic filling/finish equipment and associated isolator or barrier technologies, inspection systems, device assembly, packaging machinery, robotics, motion control, or other highly automated Drug Product equipment.
  • Experience leading the automation scope of a large pharmaceutical capital project from concept and design through controls development, construction, FAT/SAT, commissioning, qualification, start-up, and operational handover.
  • Hands-on engineering or technical leadership experience with platforms such as Emerson DeltaV, Rockwell Automation, Siemens, OSI PI, Werum PAS-X, or comparable DCS, PLC, SCADA/HMI, historian, and MES technologies.
  • Project Management Professional certification or equivalent project-management experience.
  • Experience with reliability engineering, asset lifecycle management, operational readiness, and maintenance strategy development.
  • Good understanding of Industry 4.0, Industrial Internet of Things, advanced analytics, and evolving digital capabilities used to transform biopharmaceutical manufacturing.
  • Experience working in a global organization and managing multiple suppliers, engineering partners, and system integrators.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.

Yahoo Finance
Oct 11th, 2026
J&J reports Q3 results on October 13 as $622.84B giant eyes $2.82 EPS

Johnson & Johnson will report third-quarter results on October 13, before the market opens. Analysts expect earnings per share (EPS) to edge up to $2.82, and the company has beaten EPS estimates in each of the past four quarters. The healthcare group, valued at $622.84 billion, has seen its stock rise 36.8% over 52 weeks. Shares are down 8.1% from their September 2 high of $281.07. In the second quarter, sales rose 6.6% to $25.31 billion, and adjusted EPS climbed 4.7% to $2.90. J&J raised its 2026 adjusted EPS estimate from $11.55 to $11.68. Of 25 analysts, 14 rate the stock "Strong Buy." The consensus price target of $282.60 implies 9.3% upside.